Published in Mol Pharmacol on September 01, 2002
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol (2015) 1.17
Regulation of ecto-apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3). FASEB J (2013) 0.81
Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis (2014) 0.81
3,5,6,7,8,3',4'-heptamethoxyflavone, a citrus polymethoxylated flavone, attenuates inflammation in the mouse hippocampus. Brain Sci (2015) 0.79
A new nonhydrolyzable reactive cGMP analogue, (Rp)-guanosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate, which targets the cGMP binding site of human platelet PDE3A. Bioorg Chem (2008) 0.75
The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target. PLoS Negl Trop Dis (2017) 0.75
Effect of heparin on the activation of factor XII and the contact system in plasma. Thromb Haemost (1991) 2.29
Platelet function in hyperlipoproteinemia. N Engl J Med (1974) 2.23
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation. Dig Liver Dis (2005) 2.18
Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med (1983) 2.18
A new iterative procedure for combining direct methods with solvent flattening - dealing with the phase ambiguity in protein crystallography. Acta Crystallogr D Biol Crystallogr (1997) 2.12
Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg (1996) 2.11
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (2000) 1.98
Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept (2000) 1.91
Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest (1975) 1.88
Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK506 in Cryptococcus neoformans. Mol Microbiol (2001) 1.87
Disseminated intravascular coagulation (DIC): an approach. Am J Med (1972) 1.87
Acquirement of cold sensitivity by quadruple deletion of the cspA family and its suppression by PNPase S1 domain in Escherichia coli. Mol Microbiol (2001) 1.70
Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A (1976) 1.69
Crystal structures of the monofunctional chorismate mutase from Bacillus subtilis and its complex with a transition state analog. Proc Natl Acad Sci U S A (1993) 1.69
Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med (1992) 1.65
Coagulation studies in the hyperacute and other forms of renal-allograft rejection. N Engl J Med (1969) 1.62
Purification and characterization of a potent 70-kDa thiol lysyl-proteinase (Lys-gingivain) from Porphyromonas gingivalis that cleaves kininogens and fibrinogen. J Biol Chem (1993) 1.61
Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest (1975) 1.55
Plasma kallikrein and Hageman factor in Gram-negative bacteremia. Ann Intern Med (1970) 1.53
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest (1969) 1.52
Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest (1982) 1.45
The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med (1969) 1.45
Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun (1969) 1.44
Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J Clin Invest (1977) 1.42
Lack of clinically significant contact system activation during platelet concentrate filtration by leukocyte removal filters. Blood (1998) 1.42
Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry (1981) 1.41
Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J Clin Invest (1984) 1.40
Invited letter concerning: aprotinin. J Thorac Cardiovasc Surg (1991) 1.40
Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood (1986) 1.38
The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest (1993) 1.38
Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest (1984) 1.35
Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity. Structure (1997) 1.34
Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest (1969) 1.34
More on kininogen measurements in platelet concentrates that are white cell (WBC) reduced with WBC-reduction filters. Transfusion (1996) 1.33
Crystallographic studies of the catalytic mechanism of the neutral form of fructose-1,6-bisphosphatase. Biochemistry (1993) 1.27
Neutrophil elastase-releasing factors in bronchoalveolar lavage from patients with adult respiratory distress syndrome. Am Rev Respir Dis (1985) 1.27
Crystal structure implies that cyclophilin predominantly catalyzes the trans to cis isomerization. Biochemistry (1996) 1.26
Circulating anticoagulants to factor VIII. Immunochemical studies and clinical response to factor VIII concentrates. Am J Med (1970) 1.26
Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry (1984) 1.25
Origin of the high molecular weight activator of prekallikrein. J Biol Chem (1973) 1.22
Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest (1983) 1.22
Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest (1982) 1.21
Formation of human plasma kinin. N Engl J Med (1974) 1.21
Structure of NaeI-DNA complex reveals dual-mode DNA recognition and complete dimer rearrangement. Nat Struct Biol (2001) 1.19
Detection and use of pseudo-translation in determination of protein structures. Acta Crystallogr D Biol Crystallogr (1998) 1.17
Human plasma prekallikrein: a rapid high-yield method for purification. Eur J Biochem (1979) 1.17
The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem (1985) 1.17
Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb (1992) 1.16
Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture. J Clin Invest (1975) 1.16
A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. N Engl J Med (1970) 1.14
Periodontal breakdown in the Dmp1 null mouse model of hypophosphatemic rickets. J Dent Res (2008) 1.14
Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest (1982) 1.13
Identification of adenine nucleotide binding proteins in human platelet membranes by affinity labeling with 5'-p-flurosulfonylbenzoyl adenosine. J Biol Chem (1978) 1.11
Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem (1992) 1.11
Subcellular localization and secretion of factor V from human platelets. Proc Natl Acad Sci U S A (1981) 1.09
Critical role of the carbohydrate side chains of collagen in platelet aggregation. J Clin Invest (1972) 1.09
Cyclic AMP metabolism in cholesterol-rich platelets. J Biol Chem (1977) 1.09
A primate model of hyperacute renal allograft rejection. Am J Pathol (1975) 1.09
Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation (1996) 1.08
Human neutrophils contain and bind high molecular weight kininogen. J Clin Invest (1989) 1.07
The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem (1994) 1.06
Chronic intravascular coagulation syndrome. N Engl J Med (1968) 1.06
Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J (2001) 1.05
Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. J Clin Invest (1986) 1.05
Disseminated intravascular coagulation. Approach to treatment. Drugs (1992) 1.04
Mechanistic implication of crystal structures of the cyclophilin-dipeptide complexes. Biochemistry (1996) 1.04
Fibronectin degradation products containing the cytoadhesive tetrapeptide stimulate human neutrophil degranulation. J Clin Invest (1988) 1.03
High-molecular weight kininogen. A secreted platelet protein. J Clin Invest (1983) 1.03
Crystal structure of NaeI-an evolutionary bridge between DNA endonuclease and topoisomerase. EMBO J (2000) 1.03
Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody. Proc Natl Acad Sci U S A (1985) 1.02
Potentiation of the function of Hageman factor fragments by high molecular weight kininogen. J Clin Invest (1977) 1.01
Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg (1993) 1.01
Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. Hum Pathol (1972) 1.01
Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood (1991) 1.01
High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry (1982) 1.00
Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J Thromb Haemost (2005) 0.99
Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood (2000) 0.99
The skin in disseminated intravascular coagulation. Prospective analysis of thirty-six cases. Br J Dermatol (1973) 0.99
Abnormalities of cholesterol-phospholipid composition in platelets and low-density lipoproteins of human hyperbetalipoproteinemia. J Lab Clin Med (1977) 0.98
Kinin activation in the blood of patients with sepsis. Surg Gynecol Obstet (1976) 0.98
Naturally occurring human antibodies against two distinct functional domains in the heavy chain of FXI/FXIa. Blood (1988) 0.98
Evaluation of a microassay for human plasma prekallikrein. J Lab Clin Med (1987) 0.97
Human platelet collagenase. J Clin Invest (1974) 0.97
cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A (1988) 0.97
High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem (1994) 0.97
Crystal structures of 1-aminocyclopropane-1-carboxylate (ACC) synthase in complex with aminoethoxyvinylglycine and pyridoxal-5'-phosphate provide new insight into catalytic mechanisms. J Biol Chem (2001) 0.97
Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol (2001) 0.97
Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. Proc Natl Acad Sci U S A (1992) 0.96
Activation of Hageman factor in the nephrotic syndrome. Am J Med (1974) 0.96
Disseminated intravascular coagulation: a reappraisal. Annu Rev Med (1979) 0.96
Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest (1984) 0.96
Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol (1992) 0.95
Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood (1989) 0.95
Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest (1978) 0.94
Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem (2000) 0.94
Selective kallikrein-kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology (1996) 0.94
Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem (1985) 0.94
Cleaved high molecular weight kininogen inhibits tube formation of endothelial progenitor cells via suppression of matrix metalloproteinase 2. J Thromb Haemost (2009) 0.94